120
Participants
Start Date
March 30, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
June 30, 2026
A1: SHR-A1811
A1: an anti-HER2 antibody-drug conjugate (ADC)
A2: SHR-A1811 with Camrelizumab
"A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~Camrelizumab: an anti-programmed death-1 (PD-1) antibody"
B1: TROP2 ADC
B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
B2: TROP2 ADC with Camrelizumab
"B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~Camrelizumab: an anti-programmed death-1 (PD-1) antibody"
C1: SHR-A1811
C1: an anti-HER2 antibody-drug conjugate (ADC)
C2: SHR-A1811 with BP102
"C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)"
D1: TROP2 ADC
D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
D2: TROP2 ADC with BP102
"D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)"
E1: SHR-A1811
E1: an anti-HER2 antibody-drug conjugate (ADC)
F1: TROP2 ADC
F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
G1: SHR-A1811
G1: an anti-HER2 antibody-drug conjugate (ADC)
H1: TROP2 ADC
H1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
Fudan University
OTHER